ClinicalTrials.Veeva

Menu
Endoscopic Research | Orlando, FL logo

Endoscopic Research | Orlando, FL

Research site

Site insights

Top conditions

Top treatments

Risankizumab
Upadacitinib
ABT-494
APT-1011
Ustekinumab
RVT-3101
ABX464
Vedolizumab
MK-7240
Lutikizumab

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Active trials

16 of 33 total trials

A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433 (U-ENDURE)

A multicenter study to evaluate the efficacy and safety of maintenance and long-term treatment administration of upadacitinib, an orally administered...

Active, not recruiting
Crohn's Disease
Drug: Placebo for Upadacitinib
Drug: Upadacitinib

The purpose of this study is to evaluate the safety and effectiveness of JNJ-77242113 compared with placebo in participants with moderately to severe...

Active, not recruiting
Colitis, Ulcerative
Drug: Placebo
Drug: JNJ-77242113

The study consists of 4 sub-studies, as follows:* Sub-study 1 (Randomized, double-blind, placebo controlled study) to evaluate the efficacy and safet...

Active, not recruiting
Crohn's Disease
Drug: Placebo for Risankizumab IV
Drug: Risankizumab SC

The main aim of this study is to learn about the effect of treatment with vedolizumab IV (vedolizumab) together with adalimumab or vedolizumab togeth...

Enrolling
Crohn's Disease
Drug: Vedolizumab
Drug: Adalimumab

The main aim of this study is to learn about the effect of treatment with vedolizumab IV (vedolizumab) together with tofacitinib in adults with moder...

Enrolling
Ulcerative Colitis
Drug: Tofacitinib
Drug: Vedolizumab

Crohn's disease (CD) is a long-lasting disease that causes severe inflammation (redness, swelling), in the digestive tract, most often affecting the...

Enrolling
Crohn's Disease
Drug: Placebo for risankizumab
Drug: Risankizumab SC

The purpose of this study is to evaluate safety and efficacy of risankizumab in participants with ulcerative colitis (UC) in participants who respond...

Active, not recruiting
Ulcerative Colitis (UC)
Drug: placebo for risankizumab
Drug: risankizumab

The purpose of this protocol is to evaluate the efficacy and safety of tulisokibart in participants with moderately to severely active Crohn's diseas...

Enrolling
Crohn's Disease
Other: SC Placebo
Drug: IV Tulisokibart

This study is designed to evaluate the long-term safety and efficacy of Upadacitinib in participants with ulcerative colitis (UC) who have not respon...

Active, not recruiting
Ulcerative Colitis (UC)
Drug: Placebo
Drug: Upadacitinib (ABT-494)

This is a multicenter, randomized, placebo-controlled study to evaluate the long-term efficacy and safety of ABX464 50mg and 25mg administered once d...

Enrolling
Ulcerative Colitis
Drug: ABX464
Drug: Placebo

This is a multicenter, randomized, placebo controlled study to evaluate the efficacy and safety of ABX464 given at 25 or 50 mg QD in inducing clinica...

Enrolling
Ulcerative Colitis
Drug: ABX464
Drug: Placebo

This Phase 2, randomized, double-blind, multicenter, induction and maintenance study is designed to evaluate the safety and efficacy of RO7790121 (RV...

Active, not recruiting
Crohns Disease
Drug: RO7790121

This Phase 2, randomized, double-blind, multicenter, induction and maintenance study is designed to evaluate the safety and efficacy of RVT-3101 in a...

Active, not recruiting
Crohn Disease
Drug: RVT-3101

Crohn's disease (CD) is a long-lasting condition causing inflammation that can affect any part of the gut. This study will evaluate how well risankiz...

Active, not recruiting
Crohn's Disease (CD)
Drug: Risankizumab
Drug: Ustekinumab

Ulcerative colitis (UC) is a type of inflammatory bowel disease that causes inflammation and bleeding from the lining of the rectum and colon (large...

Active, not recruiting
Ulcerative Colitis
Drug: ABBV-668

Crohn's disease (CD) is a long-lasting disease that causes severe inflammation (redness, swelling), in the digestive tract, most frequently affecting...

Enrolling
Crohn's Disease
Drug: Risankizumab
Drug: Lutikizumab

Trial sponsors

AbbVie logo
E
A
Lilly logo
Roche logo
Takeda logo
Exact Sciences Corporation logo
Janssen (J&J Innovative Medicine) logo
Merck Sharp & Dohme (MSD) logo
R

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems